Abstract:SARS-CoV-2-neutralizing antibodies were substantially expanded one month after a shot of XBB.1.5 monovalent mRNA vaccine (XBB.1.5 MV) booster, but the durability of this response remained unknown. Here, we addressed this question by performing neutralization assays on four viral variants (D614G, BA.5, XBB.1.5, and JN.1) using sera from 39 adult participants obtained at ∼1 month and ∼3 months post an XBB.1.5 MV booster. Our findings indicate that the resultant neutralizing antibody titers were robust and generally maintained at stable levels for the study period, similar to those following XBB infection. Importantly, this durability of neutralizing antibody titers contrasts with the decline observed after a booster of the original monovalent or BA.5 bivalent mRNA vaccine. Our results are in line with the recent national data from the Centers for Disease Control and Prevention, showing the efficacy against symptomatic SARS-CoV-2 infection is sustained for up to 4 months after an XBB.1.5 MV booster.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to explore the persistence of neutralizing antibodies after the administration of the XBB.1.5 monovalent mRNA vaccine booster. Specifically, the researchers evaluated the neutralizing ability of these antibodies against four virus variants (D614G, BA.5, XBB.1.5, and JN.1) and their changes over time by detecting the neutralizing antibody titers at different time points (approximately 1 month and approximately 3 months) after the booster vaccination. ### Main findings 1. **Persistence of neutralizing antibody titers**: - After the administration of the XBB.1.5 monovalent mRNA vaccine booster, the neutralizing antibody titers remained stable at approximately 1 month and approximately 3 months, and the titers were relatively high (>256). - This persistence is in sharp contrast to the decline in antibody titers after the administration of the original monovalent or BA.5 bivalent mRNA vaccine boosters. 2. **Comparison among different groups**: - The study was divided into four cohorts: those who received only the XBB.1.5 monovalent mRNA vaccine booster, those who were only infected with the XBB sub - lineage virus, those who received the XBB.1.5 monovalent mRNA vaccine booster after being infected with the pre - XBB Omicron sub - lineage virus, and those who received the XBB.1.5 monovalent mRNA vaccine booster after being infected with the XBB sub - lineage virus. - Individuals who received the XBB.1.5 monovalent mRNA vaccine booster after being infected with the XBB sub - lineage virus had significantly higher neutralizing antibody titers against all tested viruses than those who received only the XBB.1.5 monovalent mRNA vaccine booster. 3. **Antigenic map analysis**: - The antigenic map showed that infection with the XBB sub - lineage virus seemed to reduce the antigenic distance more than a single XBB.1.5 monovalent mRNA vaccine booster. - Receiving the XBB.1.5 monovalent mRNA vaccine booster after having a history of Omicron infection enhanced the neutralizing ability against the currently dominant JN.1 sub - lineage virus. 4. **Antibody decay rate**: - Compared with previous wild - type monovalent or ancestral/BA.5 bivalent mRNA vaccine boosters, the antibody decay rate after the XBB.1.5 monovalent mRNA vaccine booster was significantly lower. ### Conclusion The XBB.1.5 monovalent mRNA vaccine booster can induce a strong and long - lasting neutralizing antibody response, and this response remains stable within approximately 3 months after vaccination. This finding is consistent with the recent estimates of vaccine effectiveness reported by the US Centers for Disease Control and Prevention (CDC), indicating that the protection effect after receiving the updated vaccine does not decline significantly within 4 months.

Robust SARS-CoV-2 Neutralizing Antibodies Sustained through Three Months Post XBB.1.5 mRNA Vaccine Booster

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination

Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?

XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1

Enhanced neutralization of SARS-CoV-2 XBB sub-lineages and BA.2.86 by a tetravalent COVID-19 vaccine booster

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants

Waning immunity and IgG4 responses following bivalent mRNA boosting

Changes in Serum-Neutralizing Antibody Potency and Breadth Post-Sars-cov-2 Mrna Vaccine Boost.

Enhanced neutralization of SARS-CoV-2 variant BA.2.86 and XBB sub-lineages by a tetravalent COVID-19 vaccine booster

Enhanced Neutralization of SARS-CoV-2 by a Tetravalent COVID-19 Vaccine Booster

Monovalent XBB.1.5 mRNA Vaccine Recalls a More Durable and Coordinated Antibody Response to SARS-CoV-2 Spike than the Bivalent WT/BA.5 mRNA Vaccine

Long-term Variations and Potency of Neutralizing Antibodies Against Omicron Subvariants after CoronaVac-inactivated Booster: A 7-Month Follow-Up Study.

Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients

Heterologous Prime-Boost with Mrna-1273 Stimulates Persistent Neutralising Antibodies in BBIBP-CorV-vaccinated Individuals

Long-Term Immunity against SARS-CoV-2 Wild-Type and Omicron XBB.1.5 in Indonesian Residents after Vaccination and Infection

Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters

Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection

Durability of humoral and cellular immunity six months after the BNT162b2 bivalent booster